Headlines

Go To Pro Hockey Rumors
Go To Hoops Rumors

Chris Sale

Looking Ahead To Club Options: NL East

By | at

MLBTR continues our division by division look at next year’s team/mutual option class with the NL East. Only three teams in the division have such options, though Atlanta’s group of decisions involve some of the more notable players in the class.

Previous installments: player options/opt-outs, NL West, AL West, NL Central, AL Central

Atlanta Braves

This is the final guaranteed season of the $35MM extension which Albies signed early in 2019. The deal was widely considered a massively team-friendly contract the day it happened, and that has proven to be the case. Albies has made a pair of All-Star teams, won two Silver Slugger Awards, and twice found his name on MVP ballots over the course of the deal.

There’s no intrigue to this one. The Braves will exercise the option, which ends up being a $3MM investment after factoring in the $4MM buyout. There will be another $7MM club option (with no buyout) for 2027 that will probably be a similarly easy call. Albies’ offense has declined over the past two seasons, as he’s hitting just .246/.300/.398 in 553 plate appearances since the start of 2024. The $3MM difference between the option price and the buyout is low-end utility player money, though. Even if the Braves start to question whether Albies remains the answer at second base, there’d be surplus trade value.

Atlanta signed Arcia to a three-year, $7.3MM extension on the eve of the 2023 season. It looked like an odd move at the time, an unnecessary multi-year commitment for a likely utility infielder. Then Arcia broke out with an All-Star season while replacing Dansby Swanson as Atlanta’s everyday shortstop. The contract looked like a major coup for the front office.

Things have swung back in the opposite direction over the past year-plus. Arcia’s bat cratered last year, as he turned in a .218/.271/.354 line over 602 plate appearances. While the Braves stuck with him as their starting shortstop, he’s lost that role with a dismal start to the ’25 season. Arcia has hit .200 with eight strikeouts, one walk, and one extra-base hit (a double) through 31 trips. Nick Allen jumped him on the depth chart and has started the past five games. Arcia wouldn’t need to do much to convince the Braves to exercise an option that amounts to a $1MM decision, but he’s no longer a lock to even stick on the roster all season.

Johnson dominated over 24 appearances after being acquired from the Rockies at the 2023 deadline. The righty would have been one of the better setup men in the following free agent class, but the Braves signed him to a two-year extension with a $14.25MM guarantee to keep him off the market. He has made consecutive $7MM salaries and has a matching club option with a $250K buyout for next season.

It has worked out nicely. Johnson fired 56 1/3 innings of 3.67 ERA ball with a strong 28.4% strikeout rate last year. He has punched out 10 while allowing four runs through 9 1/3 frames to begin this season. His whiffs are slightly down, while opponents are making more hard contact than they did a season ago. Those are worth monitoring, but Johnson’s overall body of work in Atlanta consists of a 2.89 earned run average with 109 strikeouts over 89 1/3 innings. As of now, a $6.75MM price point seems like solid value.

Sale’s first season in Atlanta was brilliant. He posted an MLB-best 2.38 ERA while leading the National League with 225 strikeouts. He won his first career Cy Young award after finishing in the top six on seven occasions earlier in his career. He reestablished himself as an ace following some injury-plagued years. The trade in which he was acquired from the Red Sox for struggling second baseman Vaughn Grissom has been a steal.

The left-hander’s uneven start to 2025 has contributed to the Braves’ mediocre April. Sale has allowed 5.40 earned runs per nine through his first six outings. They’ve gone 3-3 in those contests. It’s largely the product of an inflated .400 batting average on balls in play against him. Sale’s 27.3% strikeout rate is down nearly five percentage points relative to last season, but it remains a well above-average mark for a starting pitcher. He’s getting whiffs on 12.9% of his offerings. His slider has been as lethal as ever. Opponents have feasted on his fastball so far, but there’s no dramatic change in velocity or spin. While the poor start has probably tanked his chance of repeating as the Cy Young winner, the $18MM option still seems like an easy “yes” for the front office.

Miami Marlins

  • None

New York Mets

Over the weekend, Raley reportedly agreed to terms with the Mets on a one-year deal with a club option. The signing has not been finalized, nor has the money been reported. Raley is working back from last May’s Tommy John surgery.

The Mets also re-signed Smith on a one-year deal with an option after TJS — a July operation, in his case. He’s making $1MM for what will probably be a completely lost season. The Mets get an affordable $2MM option for next season that they’re likely to exercise so long as Smith doesn’t suffer a setback. If they do pick it up, he could earn another $750K based on his appearance total next season. Smith would make $50K apiece at 30, 35, and 40 appearances; $75K for 45 and 50 games; $100K at 55 and 60 appearances; and $125K each for 65 and 70 games. He owns a 3.48 ERA over parts of six seasons as a quality middle reliever for New York.

Philadelphia Phillies

Alvarado signed for two years and $18.55MM in new money on a deal covering the 2024-25 seasons. He has made $9MM salaries in each of the past two years and has a matching option with a $500K buyout. That’s a little below the market rate for high-leverage relievers, which Alvarado has proven himself to be.

Over parts of five seasons with the Phils, the lefty carries a 3.34 earned run average. Bouts of wildness have led to some inconsistency, but he’s shown the ability to miss bats at plus rates while throwing as hard as any left-hander in the sport. Alvarado’s 24.4% strikeout rate last season was oddly pedestrian, but he’s fanned nearly 30% of batters faced in his career.

He has been back at peak form to begin this season. He has punched out 18 of 56 hitters (32.1%) while allowing only three runs through 13 2/3 innings. Alvarado has collected five saves and a pair of holds without blowing a lead, and he’s operating with career-best control (3.6% walk rate). It’s tough to envision him continuing to throw this many strikes — he walked more than 10% of opponents in seven consecutive years leading up to this one — but he’s the Phils’ most trusted reliever right now. This is tending towards an easy pickup.

Shortly before Opening Day last year, Strahm preemptively signed a one-year extension covering the 2025 season. The lefty is making $7.5MM this year and has a club/vesting option for next season. It begins as a $4.5MM team option. The price would jump by $1MM apiece if he reaches 40, 50 and 60 innings pitched this year. If he hits 60 innings and passes a postseason physical, it vests at $7.5MM. It’s a straight vesting option, not one with an opt-out, so Strahm would return on a guaranteed deal if it triggers.

That’s a result with which the Phillies would probably be happy. Strahm turned in an excellent ’24 campaign, working to a 1.87 ERA while striking out a third of opposing hitters over 66 appearances. He has fanned 15 through his first 11 2/3 frames this year. Strahm has surrendered five runs, four earned, on 11 hits and four walks. His 91.8 MPH average four-seam fastball is down from last season’s 93.4 mark, which is a little alarming, but the results have been solid and he remains one of the more reliable setup options for skipper Rob Thomson.

Washington Nationals

  • None

NL East Notes: Sale, Montas, Wood

By | at

Braves left-hander Chris Sale just had a tremendous bounceback season. He made 29 starts with a 2.38 earned run average, earning a National League Cy Young award. He was largely injured and/or ineffective from 2019 to 2023, which had him pondering retirement.

“I thought that it was gonna be my last year,” Sale said to the Baseball Isn’t Boring podcast about where he was at before getting traded to Atlanta. “So I went into that offseason on a mission like ’one more year left.’… ’cause in my mind, I wasn’t walking away from baseball. I was walking away from getting hurt.”

The Red Sox traded Sale to Atlanta for Vaughn Grissom in December of 2023. At the time, as mentioned, he had been battling significant injuries for five years. Tommy John surgery in 2020 was the big one but Sale also had a stress reaction in his ribs, a fractured finger, a broken wrist suffered in a bicycle accident and a stress reaction in his shoulder blade over that span. He had a 4.16 ERA in 298 1/3 innings over those five seasons.

2024 was the final year of his extension with the Red Sox and the mounting injuries apparently had him looking towards hanging up his spikes. But he was traded to Atlanta, signed an extension that covered 2024 and 2025 with a club option for 2026, and then went on to have an excellent season in 2024. It makes for an interesting “what if” but Sale is clearly in a better spot now. The injury bug hasn’t left him entirely alone, however. He missed the final two weeks of 2024 due to back spasms and was also left off Atlanta’s postseason roster. 2024 was still a big improvement over prior years but time will tell if he can keep the good health going into his age-36 season.

Some more spring training tidbits from the NL East…

  • It was reported earlier this week that Mets righty Frankie Montas has a lat strain and will be shut down for six to eight weeks. The righty is apparently a bit more optimistic than his club, however. He told members of the media today, including Anthony DiComo of MLB.com, that he’s already feeling better from his platelet-rich plasma injection and expects to be throwing again in four to six weeks. That’s still a notable period of time but it’s a bit less dire than the other timeline. He had a 4.84 ERA last year and then signed a two-year, $34MM deal with the Mets this winter. He will have the chance to opt out after the first year, though returning healthy and productive will be important if he is to consider that possibility. For now, the Mets’ rotation mix includes Sean Manaea, Kodai Senga, David Peterson, Clay Holmes, Paul Blackburn, Griffin Canning and Tylor Megill.
  • Nationals outfielder James Wood has some quad tendinitis, per Andrew Golden of The Washington Post. It doesn’t bother him when he hits, so he’s been able to take batting practice but has skipped some defensive drills. Per Mark Zuckerman of MASNsports.com, Wood says he has “zero” concern but the club did send him for an MRI, which showed no structural damage. With still over a month before Opening Day, there’s plenty of time to get things in order, with Wood and the Nats both surely hoping for a clean bill of health by then. Now just 22 years old, Wood hit .264/.354/.427 in his major league debut last year and is slated to be a big part of the club’s future.

Chris Sale Wins National League Cy Young Award

By | at

Braves left-hander Chris Sale has been named the National League Cy Young Award winner for 2024, per an announcement from the Baseball Writers Association of America. Zack Wheeler of the Phillies finished in second place with Paul Skenes of the Pirates in third place.

The award is the final cherry on top of a remarkable comeback season for Sale. He had a run from 2010 to 2018 of being one of the best pitchers in the majors, but struggled in 2019 and then was in the injury wilderness for quite a while. Due to various ailments, including Tommy John surgery, he only pitched about 150 innings total from 2020 to 2023.

The Red Sox flipped him to Atlanta almost a year ago, in December of 2023. The move was seen as risky at the time, as Sale was going into his age-35 season and was several years removed from his prime.

On top of that, Atlanta sent Vaughn Grissom to Boston in the deal, a notable prospect who still had years and years of cheap control. In return, they were getting just one year of Sale, though they did sign him to an extension that covered 2024 and 2025 with a club option for 2026. That extended their window of control over him, but at a fairly hefty price point: $38MM for the two guaranteed years plus $18MM for the option.

But so far, the deal has been incredibly lopsided in favor of Atlanta. Grissom was injured for much of 2024 and didn’t perform well while healthy. For Atlanta, most of their key contributors got hurt this year while Sale ironically stayed healthy, in spite of his recent track record.

Sale finished the season having made 29 starts and thrown 177 2/3 innings, allowing 2.38 earned runs per nine. He struck out 32.1% of batters faced, only gave out walks 5.6% of the time and got grounders on 44.8% of balls in play. He won the pitching triple crown by leading the National League in ERA, wins and strikeouts. His tally of 6.4 wins above replacement from FanGraphs was easily the most in the majors this year, with Tarik Skubal of the Tigers second at 5.9 fWAR.

Despite his previous dominance, this is actually Sale’s first time taking home the hardware. Per MLB’s Sarah Langs on X, Sale is the first pitcher to finish top five in Cy Young voting in five straight years, fall outside the top five for five straight years immediately after, followed by a return to the top five. He is also (X links from Langs) the first pitcher to have six previous top five finishes and later win the award, in addition to being one of the five oldest pitchers to win for the first time.

Sale got 26 of the first place votes (full vote tallies from the BBWAA), with the other four going to Wheeler, who logged exactly 200 innings over 32 starts with a 2.57 ERA. Skenes already won Rookie of the Year award earlier this week but this further cements what an amazing season he had. Other pitchers getting votes were Dylan Cease, Shota Imanaga, Logan Webb, Michael King, Hunter Greene, Ryan Helsley, Cristopher Sánchez, Reynaldo López, Sean Manaea and Aaron Nola.

Gold Glove Winners Announced

By | at

Major League Baseball announced the Gold Glove winners tonight, as selected by a group of managers, coaches, and statistical analysis.  Twenty-five percent of the selection total was determined by SABR’s Defensive Index metrics, while the other 75 percent was determined by votes from all 30 managers and up to six coaches from each team.  The utility Gold Glove was determined in a separate fashion, via a defensive formula calculated by SABR and Rawlings.

National League winners….

American League winners….

Chris Sale Not On Braves’ Wild Card Roster

By | at

The Braves announced their roster for the Wild Card series today and it does not include left-hander Chris Sale. The club is going with an even split of 13 pitchers and position players, the latter group including two catchers, five infielders and six outfielders.

Sale had an excellent bounceback season in 2024 and could be awarded a Cy Young trophy in a few weeks, but the campaign ended on a frustrating note. He hasn’t taken the mound since September 19 against the Reds. In that outing, Sale’s velocity was down and he hasn’t pitched since. Up until yesterday, it seemed as though the club was just holding Sale to see if they would need him for a do-or-die game, otherwise hoping to hold him back for the first game of the Wild Card round.

Going into yesterday’s double-header, which was necessitated after two midweek games between the Mets and Atlanta were delayed by Hurricane Helene, both clubs needed a victory to secure a playoff spot. Spencer Schwellenbach started Game 1, which the Mets went on to win 8-7. It was expected that Sale would take the ball for the second contest but the club then announced that Sale had been scratched with back spasms. The issue had flared up during that start against the Reds and he kept hoping to be able to return to the mound but it didn’t improve and then worsened on Sunday night, per Mark Bowman of MLB.com (X links).

Based on Sale being left off the Wild Card roster, it can be assumed that the club doesn’t expect him to be game ready in the next few days. As mentioned, he is having a great season and undoubtedly would have been a part of their plans if he were healthy. He made 29 starts this year with a 2.38 earned run average, 32.1% strikeout rate, 5.6% walk rate and 44.8% ground ball rate.

Without Sale, the club will have to get creative to survive against the Padres. Due to the aforementioned double-header situation, they used a lot of arms yesterday. Schwellenbach started the first game and Grant Holmes the second. Neither of those pitchers are on the roster either, which makes sense since they probably wouldn’t be available for a few days anyway.

Max Fried and Reynaldo López will likely start game two and three respectively, as they would be on normal rest for those contests following their last regular season outings. Charlie Morton started on Sunday and might not be available early in the series, though he is on the roster.

For today, the club may be looking to get some innings out of Bryce Elder or AJ Smith-Shawver. Neither has been a huge part of the club’s performance of late but they may need to step up while the bullpen is taxed and the club can’t turn to Sale, Schwellenbach or Holmes. Elder posted a 6.52 ERA in the big leagues this year while frequently being optioned to the minors. He had a solid 3.73 ERA in Triple-A this year but hasn’t pitched for the big league club since August 6.

Smith-Shawver only pitched once in the majors this year, a spot start of 4 1/3 innings in May. He has a 4.85 ERA in Triple-A on the year, though he finished somewhat strong with a 3.68 ERA over his last seven starts.

In addition to Elder and Smith-Shawver, Atlanta’s playoff roster consists of Fried, Lopez, Morton, Aaron Bummer, Jesse Chavez, Daysbel Hernández, Raisel Iglesias, Luke Jackson, Joe Jiménez, Pierce Johnson and Dylan Lee. On the position player side, they have catchers Sean Murphy and Travis d’Arnaud, infielders Ozzie Albies, Orlando Arcia, Whit Merrifield, Matt Olson and Gio Urshela, as well as outfielders Michael Harris II, Jarred Kelenic, Ramón Laureano, Marcell Ozuna, Jorge Soler and Eli White.

The Other, Other NL MVP Candidate

By | at

For much of the season Shohei Ohtani has been the presumptive National League MVP favorite. Maybe that wasn't the case on Opening Day, but an injury to teammate Mookie Betts early in the summer and an injury to D-backs star infielder Ketel Marte cleared his path. The Ohtani hype is understandable. He's been the National League's best hitter this year by many measures, pacing the Senior Circuit in slugging percentage (.613) and wRC+ (167). Ohtani is fifth in the NL in batting average, fourth in OBP, first in homers and runs scored and second in runs batted in. He's also swiped 46 bags and is a veritable lock to have a 45-45 season, with a chance at becoming MLB's first ever 50-homer, 50-steal player in a season.

Lately, there's been a push by Mets shortstop Francisco Lindor to tighten the race, however. Dating back to July 1, Lindor boasts a sensational .310/.384/.587 slash. He's in the midst of a torrid 15-game hitting streak, which he started just one game after seeing a 12-game hitting streak end. Since the beginning of July, Lindor has more than twice as many multi-hit games (22) than he does hitless games (10). Defensive metrics are a bit split on him this year, with Defensive Runs Saved curiously pegging him as average while Statcast grades him as one of the best defensive players in the entire game. Regardless, Lindor and his .274/.343/.501 batting line (plus 30 homers and 26 steals)  lead the NL in both FanGraphs and Baseball-Reference WAR.

It's not quite fair to the rest of the field to call this a pure two-horse race, though Lindor and Ohtani are certainly the favorites at the moment. Cincinnati standout Elly De La Cruz could thrust himself further into the conversation with a big finish, but many voters will be turned off by the fact that however excellent his season has been -- and it's been excellent -- it's happened as a member of a non-contending Reds club.

There's still one other viable MVP candidate who's not getting the love, and who probably won't get the love -- but absolutely should.

Unlock Subscriber-Exclusive Articles Like This One With a Trade Rumors Front Office Subscription

BENEFITS
  • Access weekly subscriber-only articles by Tim Dierkes, Steve Adams, and Anthony Franco.
  • Join exclusive weekly live chats with Anthony.
  • Remove ads and support our writers.
  • Access GM-caliber tools like our MLB Contract Tracker

AL East Notes: Sale, Tiedemann, Ramirez

By | at

The Chris Sale-for-Vaughn Grissom trade between the Braves and Red Sox caught many in baseball by surprise, including Sale himself.  The veteran southpaw related in a recent appearance on the “Baseball Isn’t Boring” podcast (hat tip to WEEI.com’s Rob Bradford) that being dealt “wasn’t even in the realm of possibilities.  That wasn’t even a thought that crossed my mind” heading into the offseason.  As Sale plainly put it, “Why would anybody want me at this point?” in the wake of multiple injury-plagued seasons.

There was also the factor of Sale’s 10-and-5 no-trade rights, so he could’ve rejected the chance to join the Braves.  However, after less than a day of discussing things with his family and inner circle, Sale okayed the deal, with some Grapefruit League geography playing a major role.  The Braves’ spring facility in North Port, Florida adds only roughly an hour to Sale’s commute from his home, so “I can still live my life while being part of this team in spring training.  That was probably the most important thing.  One hundred percent.  My kids play sports.  They’ve got school stuff going on.”  Sale also relayed the amusing item that the first proper conversation he had with Red Sox chief baseball officer Craig Breslow after weeks of texts and “phone tag” was when Breslow let Sale know the trade was in the works.

More from around the AL East…

  • Top Blue Jays pitching prospect Ricky Tiedemann is day-to-day with inflammation in his calf and hamstring area, manager John Schneider told Sportsnet’s Shi Davidi (X links) and other reporters.  It doesn’t seem like Tiedemann will be sidelined for too long since an MRI didn’t reveal any structural damage, though any kind of injury setback is perhaps more concerning given how Tiedemann missed big chunks of the 2023 season due to shoulder and biceps injuries.  After pitching just 44 minor league innings last year, Tiedemann is going to be built up slowly and steadily to the point where the Jays hope he can take on more of a regular starter’s workload, and perhaps make his MLB debut before 2024 is through.
  • Despite multiple trade rumors over the last few months, Harold Ramirez is still with the Rays, and he tells John Romano of the Tampa Bay Times that he is just focused on baseball as Spring Training games get underway.  Ramirez will earn $3.8MM this season and is arbitration-eligible next winter as well, leading to speculation that the Rays might be open to dealing an increasingly-expensive (by their payroll standards) player with limited defensive value as an outfielder.  Romano also notes that the recent signing of Amed Rosario brought another right-handed outfield option into the mix, so it still wouldn’t be a surprise if Tampa swung a late deal to move Ramirez prior to Opening Day.

NL East Notes: Harper, Sale, Crick

By | at

After his recovery from Tommy John surgery necessitated a move to first base last season, Bryce Harper took well enough to his new position that the Phillies announced in November that Harper would be their regular first baseman in 2024 and beyond.  The two-time NL MVP spoke to reporters (including The Athletic’s Matt Gelb) about the situation today, saying “I wanted them to know that I was on board with anything they wanted to do,” and that Harper left the decision about his position up to the club.  “I said if you want me in right field, I’ll play right.  If you want me at first, I’ll play first base.  I think collectively, they said, first base is where we want you.  I said, ’OK, I’ll do everything I can to be there,’ ” Harper said.  He is now spending his Spring Training further working on what seems to be his permanent new position, noting that “I don’t think I’ll move back out to right.  I don’t.  But never say never.”

Harper also confirmed that he is interested in extending his contract, as agent Scott Boras stated in December.  The idea caught many by surprise given that Harper still has eight seasons and $196MM remaining on his original 13-year, $330MM contract, and he’ll be turning 39 years old in October 2031.  While Harper said “I haven’t really thought too much about” his contract situation, he said that “playing into my 40’s, I mean, that’s the biggest thing for me.  So I want to get that done.”  It remains to be seen if Harper, Boras, and the Phillies could possibly reach some kind of deal to add two (or more?) years onto Harper’s contract, yet president of baseball operations Dave Dombrowski has downplayed the idea of a renegotiation.

More from around the NL East…

  • Chris Sale has battled through several injury-plagued seasons, but the winter of 2023-24 “was the first time going into an offseason without dealing with something since 2018 or something like that,” the new Braves starter told The Athletic’s David O’Brien and other reporters.  “It’s been a long time.  I had a lot of fun this offseason, being able to play baseball and do things that I haven’t been able to do.”  In both acquiring Sale from the Red Sox and then signing him to a two-year extension, the Braves are putting a lot of faith that the southpaw is ready to rebound as he enters his age-35 season.  Atlanta even looked into acquiring Sale during the 2023 season, according to manager Brian Snitker.
  • Mets reliever Kyle Crick is recovering from a Grade 4 calf strain and might not start throwing bullpens until closer to the end of spring camp, MLB.com’s Anthony DiComo writes.  New York signed Crick to a minor league deal in December and he has no issue with pitching in the minors for the start of the season, given how his injury will seemingly prevent him making the Opening Day roster.  Crick posted a 3.56 ERA over 187 1/3 relief innings with the Giants, Pirates, and White Sox from 2017-22, though he didn’t pitch in 2023 until surfacing in Dominican Winter League action a few months ago.
  • There’s enough happening within the division that this is our second batch of NL East Notes today.  Earlier on, Nick Deeds compiled another set of items about the Marlins, Phillies, Nationals, and Braves.

Braves, Chris Sale Agree To Two-Year Deal

By | at

The Braves and left-hander Chris Sale have agreed to a new deal, which will pay him $38MM over the next two years. The Wasserman client will earn $16MM in 2024 and $22MM in 2025 and there’s also an $18MM club option for 2026. Sale was already under contract via an extension he previously signed with the Red Sox but this will overwrite that.

Sale was acquired from the Red Sox last week, in a trade that sent Vaughn Grissom to Boston. The Sox also included $17MM to cover the remainder of Sale’s contract, a five-year, $145MM extension he and the Red Sox signed in 2019. As part of that deal, Sale was set to make $27.5MM in 2024, though $10MM of that was deferred until 15 years in the future. With the $17MM coming from the Sox, Atlanta was only going to be paying him $500K. There was also a $20MM club option for 2025.

As part of this new deal, Sale’s $16MM salary will be pretty close to the non-deferred money he was going to make in 2024. He will no longer have that deferred $10MM payment down the road, but he will have $22MM locked in for the 2025 season. That gives him some extra security in the event of more health problems cropping up this year. Sale pitched less than 50 total innings over the 2020-2022 period, mostly due to Tommy John surgery but also due to other ailments. Last year, he was able to toss 102 2/3 frames but a stress reaction in his shoulder blade kept him out of action for over two months. Any further health issues would have perhaps given the club some hesitation about picking up the 2025 option but Sale has now locked in a notable salary for next year.

For Atlanta, this is a show of faith in the soon-to-be-35-year-old. They could have simply employed Sale for 2024 and then walked away if things didn’t go well, with the club option there to keep him around if he had a strong campaign for his new club. But they have now committed themselves to at least two years of Sale, with the club option now kicked down the road to 2026. As mentioned, Sale hasn’t been fully healthy in the past four years and even had some issues before that. Some shoulder and elbow issues kept him around 150 innings in 2018 and 2019, meaning his last fully healthy campaign was 2017.

Back then, Sale was one of the best pitchers in the league, finishing that 2017 season with a 2.90 ERA. Last year, he wasn’t quite as dominant, with a 4.30 at the end of the season. The peripherals were a bit better, however, with a 29.4% strikeout rate and 6.8% walk rate that were both strong.

Despite that fairly solid bounceback season, it’s obviously a gamble to bet on a pitcher that has been hurt so much, locking him up for his age-35 and age-36 seasons. But the club has a decent amount of rotation uncertainty going forward. Max Fried is entering his final year of club control while Charlie Morton is one year from free agency as well. Morton has flirted with retirement before and is going into his age-40 season, making it possible he won’t be back in 2025.

Prior to this deal, Sale was a potential to depart as well, depending on the outcome of the club option. Now that he’s under contract for 2025, he can be pencilled into next year’s rotation next to Spencer Strider. The club will still have to fill out the rest of the rotation, but perhaps internal options like Bryce Elder, AJ Smith-Shawver and Hurston Waldrep will have taken steps forwards between now and then.

There’s also the competitive balance tax to consider. Under the current collective bargaining agreement, a player’s CBT hit is recalculated when he is traded to reflect what remains of the contract. That means that Sale was going to have a $27.5MM CBT hit prior to this deal, with the Sox absorbing $17MM of that. But that will now drop to $19MM, leaving just $2MM on Atlanta’s CBT ledger this year but $19MM next year. Going into today, the club’s CBT figure was at $276MM, per Roster Resource. That’s right against the third tax threshold of $277MM, which is a notable line to cross. Clubs that go over the third threshold have their top pick in the next draft pushed back by 10 slots, in addition to an increased tax rate. By lowering Sale’s CBT hit, the club will have a bit more breathing room to make more moves, either now or during the season.

Ultimately, it’s a pact that works for both sides. Atlanta gets a bit more luxury tax space and also, hopefully, a better rotation outlook in 2025 and maybe even 2026. Sale, meanwhile, locks in some future earnings to guard against any continued health issues.

MLBTR Podcast: Yamamoto Fallout, the Sale/Grissom Trade and Transaction Roundup

By | at

The latest episode of the MLB Trade Rumors Podcast is now live on Spotify, Apple Podcasts, and wherever you get your podcasts! Make sure you subscribe as well! You can also use the player at this link to listen, if you don’t use Spotify or Apple for podcasts.

This week, host Darragh McDonald is joined by Anthony Franco of MLB Trade Rumors to discuss…

Check out our past episodes!

The podcast intro and outro song “So Long” is provided courtesy of the band Showoff.  Check out their Facebook page here!

Show all

MLB Trade Rumors is not affiliated with Major League Baseball, MLB or MLB.com

hide arrows scroll to top